Celgene Corporation
Dec 22, 2011
Add to Briefcase

Celgene Corporation Announces the Appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access

SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 22, 2011-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access, effective January 30th. Mr. Bagger will be responsible for all government and public affairs, strategic market access, communications and patient advocacy initiatives and will report to Robert J. Hugin, Chairman and Chief Executive Officer of Celgene Corporation. The position of Senior Vice President, Corporate Affairs and Strategic Market Access is a newly created position at Celgene established to support the Company’s global expansion.

A pharmaceutical industry and public affairs veteran, Mr. Bagger joins the company after most recently serving as Chief of Staff for New Jersey Governor, Chris Christie. Previously, he served as Senior Vice President of Worldwide Public Affairs and Policy for Pfizer and was an Assistant General Counsel to Horizon Blue Cross and Blue Shield of New Jersey, as well as a practicing attorney at McCarter and English.

Mr. Bagger served as a State Senator for New Jersey from 2001-2003 and before that served for ten years in the New Jersey General Assembly. He received a bachelor’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. degree from Rutgers University Law School.

“Rich brings unparalleled expertise in the area of government and public affairs within our industry and has also served in key strategic roles at the top levels of pharmaceutical policy and communications. We believe he will add a vital perspective to our business as we advance our science and novel therapies into new areas of medicine around the world,” said Hugin.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Source: Celgene Corporation

Celgene Corporation